IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists

Tumors with the help of the surrounding environment facilitate the immune suppression in patients, and immunotherapy can counteract this inhibition. Among immunotherapeutic strategies, the immunostimulatory cytokine IL-15 could represent a serious candidate for the reactivation of antitumor immunity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of immunology (1950) 2016-07, Vol.197 (1), p.168-178
Hauptverfasser:	Desbois, Mélanie, Le Vu, Pauline, Coutzac, Clélia, Marcheteau, Elie, Béal, Coralie, Terme, Magali, Gey, Alain, Morisseau, Sébastien, Teppaz, Géraldine, Boselli, Lisa, Jacques, Yannick, Béchard, David, Tartour, Eric, Cassard, Lydie, Chaput, Nathalie
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - immunology Adenocarcinoma - therapy Animals Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Cancer Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - therapy CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology Cell Line, Tumor Cell Proliferation - drug effects Colonic Neoplasms - immunology Colonic Neoplasms - therapy Cytotoxicity, Immunologic - drug effects Drug Synergism Drug Therapy, Combination Humans Immunologic Memory - drug effects Immunotherapy - methods Interleukin-15 - metabolism Life Sciences Mice Mice, Inbred BALB C Mice, Inbred C57BL Programmed Cell Death 1 Receptor - antagonists & inhibitors Recombinant Fusion Proteins - therapeutic use Signal Transduction STAT5 Transcription Factor - metabolism Tumor Burden - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!